Egypt Alzheimer’s Therapeutics Market Analysis

Egypt Alzheimer’s Therapeutics Market Executive Summary

Egypt alzheimer’s therapeutics market valued at $13 Mn in 2022, projected to reach $30 Mn by 2030 with a 10.6% CAGR.

Memory, behaviour, and mental health are all negatively impacted by Alzheimer's disease, a neurological illness. The condition typically begins gradually, worsens over time, and makes it more difficult for the affected individual to carry out everyday duties. Because of aberrant brain changes including plaque and tangle formation, nerve cells in Alzheimer's disease eventually die. For now, there is no known treatment for Alzheimer's disease. Certain medications, nevertheless, can improve quality of life and aid with symptom management. Certain neurotransmitters in the brain are altered by these drugs to treat memory and cognitive disorders. Rivastigmine, donepezil, and memantine are a few of these drugs. A supportive environment, social and cognitive activities, and maintaining a healthy lifestyle are examples of non-pharmacological methods that may enhance overall illness management.

The incidence of Alzheimer's disease (AD) in people 50 years of age and above is estimated to be 1/1000, with little variation between Al Kharga district (1.03%) and Al Quseir city (0.97%). In all age categories, women have a greater prevalence of Alzheimer's (1.26%) than men (0.93%). Most cases of Alzheimer's fall into the moderate (43.7%) and mild (41.3%) categories. Remarkably, the prevalence of severe Alzheimer's disease cases is higher in Al Quseir city (26.2%) compared to Al Kharga district (9.5%). 7.9% of all cases of dementia are early-onset, indicating they occur before the age of 65. Males are more likely to have this type of dementia (9.1%) than females (7%). In 92.1% of cases, Alzheimer's disease develops later in life than 65 years of age. It is more common in women (93%) than in men (90.9%). In 30% of cases of early-onset Alzheimer's and 50% of cases of late-onset Alzheimer's, behavioural abnormalities are noted.

With a focus on developing early detection and diagnosis techniques, the Egyptian Academy of Scientific Research and Technology (ASRT) is actively involved in cutting-edge Alzheimer's research. ASRT is a key player in the global quest to develop possible cures for Alzheimer's disease, working in seamless collaboration with prestigious international universities. Several eminent Egyptian universities, such as Ain Shams University and Cairo University, are house to specialized research teams that are exploring potential therapy targets and exploring the complexities of Alzheimer's disease.

Market Dynamics

Market Growth Drivers

Rising Burden of Alzheimer's Disease: Egypt's demographics are changing dramatically; the country's aged population is growing quickly and is predicted to account for 20% of the country's total population by 2030. This shift in the population is correlated with an increased prevalence of age-related illnesses, like Alzheimer's disease. According to research, the current estimates of the prevalence of Alzheimer's disease in Egypt might be conservative, indicating an even larger market potential for new therapeutic approaches. Because more and more older people are developing Alzheimer's disease, there is a growing need for effective interventions. This demographic trend is a strong driver of market expansion.

Increased Awareness and Diagnosis: Growing public awareness of Alzheimer's disease and improved diagnostic tools are crucial for early diagnosis and timely treatment start, which increases the number of patients actively looking for effective drugs. Government initiatives to improve accessibility to diagnostic services and raise public awareness also act as catalysts for industry expansion. Together, these calculated moves create an atmosphere that supports early intervention and increases the market's need for efficacious pharmaceutical solutions, which contributes to the market's growth.

Emerging Treatment Options: Late-stage clinical research on Alzheimer's therapy has yielded exciting advances that address many aspects of the illness and offer promise for improved treatments. The Tau protein aggregation-focused Etermis clinical study for EMERG-01 is an illustration of how local initiatives can improve global healthcare and eventually support the expansion of the Alzheimer's medication market.

Market Restraints

High Drug Costs: Current Alzheimer's drugs are quite expensive, which puts a heavy financial burden on patients and their families. This financial cost acts as a significant market barrier by impeding the general public's ability to get treatment, especially for those with limited incomes or inadequate insurance.

Low Public Awareness: Alzheimer's disease is stigmatized, and there is a lack of understanding about the disease's symptoms and potential treatments, which can lead to a delayed diagnosis and missed possibilities for prompt intervention. The importance of public education campaigns and awareness efforts in reducing these issues must be emphasized. Moreover, the prevalent deficiency in knowledge and comprehension leads to a significant market constraint that impedes the implementation of efficacious interventions and demands heightened efforts to educate the public and medical professionals.

Complex regulatory processes: For pharmaceutical companies, navigating the drug approval process is a difficult task that could hinder the country's progress in creating therapies for Alzheimer's disease. Facilitating support mechanisms for emerging players and streamlining regulatory procedures could act as catalysts and promote an atmosphere that is favourable to innovation. It is noteworthy that the intricate and demanding regulatory environment represents a significant market constraint that can discourage pharmaceutical businesses from actively engaging in the research and development of Alzheimer's medicines.

Healthcare Policies and Regulatory Landscape

The approval and dispensing of treatment medications in Egypt are mostly governed by healthcare regulations and regulatory bodies. Under the Ministry of Health and Population, the Egyptian Drug Authority (EDA) is the main regulatory organization in charge of pharmaceuticals. Drugs are carefully assessed and approved by the EDA to guarantee their quality, safety, and efficacy before they are put on the market. To ensure continued safety, it also keeps an eye on post-marketing surveillance. The goal of Egypt's healthcare policies is to achieve a balance between advancing public health and making necessary pharmaceuticals more accessible. Pharmaceutical businesses may face barriers due to bureaucratic processes and complex regulatory regulations, which could impact the timely supply of treatment products.

Competitive Landscape

Key Players

• Eisai
• Biogen
• GlaxoSmithKline
• Novartis
• Pfizer
• Roche
• Johnson & Johnson,
• Eli Lilly
• AstraZeneca
• Merck & Co.